Premier Alternatives

Novelty Nobility

Seongnam, South Korea · Founded 2017 · Privately Held (backing)

Operator of a biotech company intended to develop antibodies and antibody-drug conjugates to overcome drug resistance. Novelty Nobility is based in Seongnam, South Korea and was founded in 2017. Its last known valuation is $10.8 million. It has raised $60.8 million.

Last price · $/share
—
Implied valuation
$10.8M
Total raised
$60.8M
Last round
—

Novelty Nobility key facts

  • Operator of a biotech company intended to develop antibodies and antibody-drug conjugates to overcome drug resistance.
  • Novelty Nobility’s last known valuation is $10.8M.
  • It has raised $60.8M; the latest was Merger/Acquisition ($10.8M) in Aug 2025.
  • Notable investors include KB Investment, Mirae Asset Capital, Shinhan Venture Investment, Johnson & Johnson Innovation - JLABS, KDB Capital — 29 tracked in total.
  • Status: Privately Held (backing).
Free account
More of Novelty Nobility with a free account
  • ·The complete investor list: 29 names
  • ·Watch Novelty Nobility: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

Novelty Nobility funding rounds

No rounds on record

No funding rounds for Novelty Nobility are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.

Pro members can request priority coverage with a 48-hour turnaround.

Novelty Nobility valuation

Novelty Nobility's last known valuation is $10.8 million. The figure stands until a priced round, a secondary trade or an institutional fund mark prices the stock again.

Novelty Nobility investors

29 investors are on record for Novelty Nobility, including KB Investment, Mirae Asset Capital, Shinhan Venture Investment and Johnson & Johnson Innovation - JLABS. By type, the record holds 8 venture capital firms and 1 hedge fund.

About Novelty Nobility

Operator of a biotech company intended to develop antibodies and antibody-drug conjugates to overcome drug resistance. The company focuses on researching novel factors for angiogenesis to develop therapeutic antibodies for treating diseases caused by the growth of aberrant blood vessels, such as retinal diseases and solid cancerous tumors, enabling clients to access new therapeutic options in ophthalmology and oncology for their patients.

Sector
Healthcare
HQ
Seongnam, South Korea
Founded
2017
Employees
35
Ownership
Privately Held (backing)

Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.

Valuation on record
$10.8M

Novelty Nobility’s last known valuation. A PrivateMarketView mark is published once fund marks, secondary prints or a priced round let us confirm it.